Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tuberculosis (TB)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    218 result(s) found for: Tuberculosis (TB). Displaying page 2 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005107-26 Sponsor Protocol Number: 242-07-208 Start Date*: 2009-04-08
    Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc.
    Full Title: A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up t...
    Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000224-41 Sponsor Protocol Number: IDANAT2 Start Date*: 2008-08-26
    Sponsor Name:University of Cologne
    Full Title: A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransfe...
    Medical condition: pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005078-40 Sponsor Protocol Number: TESEC-05 Start Date*: 2016-06-03
    Sponsor Name:Statens Serum Institut
    Full Title: A Phase III trial in subjects suspected to have tuberculosis, comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomised splitbody s...
    Medical condition: Children (28 days–4 years old) with suspected Mycobacterium tuberculosis infection Participants between 5–65 years old who attended the TB clinic due to suspicion of TB disease (HIV positive and HI...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003301-22 Sponsor Protocol Number: AC-R6 Start Date*: 2021-10-05
    Sponsor Name:Archivel Farma S.L.
    Full Title: A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB (CONSTAN)
    Medical condition: Pulmonary Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000632-27 Sponsor Protocol Number: PORT-01 Start Date*: 2022-08-03
    Sponsor Name:Radboud University Medical Center
    Full Title: Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002202-30 Sponsor Protocol Number: R207910BAC2001 Start Date*: 2004-10-18
    Sponsor Name:Tibotec Pharmaceuticals Ltd.
    Full Title: An open label study to evaluate the effects on Mycobacterium tuberculosis, safety, tolerability and pharmacokinetics of single doses of R207910, in treatment naive patients with mycobacterium tuber...
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004444-29 Sponsor Protocol Number: RID-TB:Treat Start Date*: 2020-11-25
    Sponsor Name:University College London
    Full Title: An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completio...
    Medical condition: Latent Tuberculosis infection (LTBI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date*: 2023-11-15
    Sponsor Name:Vall d'Hebron Research Institute (VHIR)
    Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
    Medical condition: Pulmonary and extrapulmonary tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002592-34 Sponsor Protocol Number: RID-TB:Dx Start Date*: 2020-08-28
    Sponsor Name:University College London
    Full Title: Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx) A randomised controlled trial to evaluate the effectiveness of using the RD-1 based C Tb s...
    Medical condition: Latent Tuberculosis infection (LTBI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005492-13 Sponsor Protocol Number: TMC207TBC1002 Start Date*: 2013-03-26
    Sponsor Name:Janssen infectious diseases BVBA
    Full Title: A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatri...
    Medical condition: Multi-drug resistant tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002063-95 Sponsor Protocol Number: ASST-ITL-FARMA-INFE-2019 Start Date*: 2020-05-29
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: A Phase 3, Open, Randomized controlled trial on Completion Rate of daily Rifapentine/Isoniazid for One Month Compared with Daily Rifampicin/Isoniazid for Three Months for the Treatment of Latent Tu...
    Medical condition: latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001438-20 Sponsor Protocol Number: ASSTBS-FARM-INF_ITL-2021 Start Date*: 2021-05-10
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Randomized controlled trial on daily Rifampicin for Four Months Compared with daily Rifampicin/Isoniazid for Three Months for the Treatment of Tuberculosis Infection among migrants: Completion Rate...
    Medical condition: Tuberculosis Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001184-24 Sponsor Protocol Number: SXT8469 Start Date*: 2013-08-20
    Sponsor Name:UMCG
    Full Title: Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients with Tuberculosis
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023189-27 Sponsor Protocol Number: RG-10-179 Start Date*: 2011-01-20
    Sponsor Name:University of Birmingham
    Full Title: The pharmacogenetics of vitamin D response in tuberculosis
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000750-21 Sponsor Protocol Number: 12/0426 Start Date*: 2013-12-18
    Sponsor Name:University College London
    Full Title: The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid for latent tuberculosis infection (LTBI)
    Medical condition: Latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003386-18 Sponsor Protocol Number: ETB Start Date*: 2013-01-10
    Sponsor Name:UMCG
    Full Title: PHARMACOKINETICS AND PHARMACODYNAMICS OF ERTAPENEM IN PATIENTS WITH TUBERCULOSIS
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003567-20 Sponsor Protocol Number: A101A Start Date*: 2017-04-21
    Sponsor Name:Dept of Infectious Diseases, Aarhus University Hospital
    Full Title: A randomised controlled trial of a 12-dose rifapentine and isoniazid (RPT+INH) regimen using direct observed therapy (DOT) versus 6 months of daily isoniazid for latent tuberculosis infection (LTBI...
    Medical condition: Latent tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004620-38 Sponsor Protocol Number: 242-12-233 Start Date*: 2019-01-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therap...
    Medical condition: Pediatric patients with multidrug-resistant tuberculosis (MDR-TB) who are receiving an optimized background regimen (OBR) of antituberculosis drugs
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005664-88 Sponsor Protocol Number: HB996 Start Date*: 2006-12-08
    Sponsor Name:University of Oxford
    Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ...
    Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003420-38 Sponsor Protocol Number: PPD1 Start Date*: 2007-12-28
    Sponsor Name:Umeå University
    Full Title: The effect of Rapydan lidocain/tetracain patch on pain-response and reproducibilty in Tuberculin test
    Medical condition: Pain response to intradermal injection of tuberculin.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064882 Procedural pain LLT
    9.1 10044726 Tuberculin test LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 09:11:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA